Spanish Red Biotech Pipeline
< Back
Diagnostics and Personalized Medicine
Home
Toggle navigation
Pipeline
DRUGS: MULTINATIONAL SUBSIDIARIES
DRUGS: NATIONAL COMPANIES
RESEARCH PLATFORMS
DIAGNOSTICS AND PERSONALIZED MEDICINE
OTHER TECHNOLOGIES
Search
Charts
DRUGS: MULTINATIONAL SUBSIDIARIES
DRUGS: NATIONAL COMPANIES
DIAGNOSTICS AND PERSONALIZED MEDICINE
OTHER TECHNOLOGIES
Green pipeline
White pipeline
Spanish Red Biotech Pipeline
/
Pipeline
/
Diagnostics and Personalized Medicine
CIBER
Biomarkers and method to predict or predict response to treatment with BRAF and MEK inhibitors (BRAFi + MEKi) and for patient follow-up
Type:
Biomarkers / Diagnostic
Therapeutic area:
Cancer
Indication:
Genetic biomarkers, Cancer
Phase:
1
R+D
Studies location: